Cargando…
Silibinin Upregulates CXCR4 Expression in Cultured Bone Marrow Cells (BMCs) Especially in Pulmonary Arterial Hypertension Rat Model
Previously we reported that silibinin ameliorated pulmonary arterial hypertension (PAH) in rat PAH models, possibly through the suppression of the CXCR4/SDF-1, until the point where PAH became a severe and irreversible condition. To further investigate how silibinin ameliorates PAH, we first attempt...
Autores principales: | Zhang, Tingting, Kawaguchi, Nanako, Tsuji, Kunikazu, Hayama, Emiko, Furutani, Yoshiyuki, Sugiyama, Hisashi, Nakanishi, Toshio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290890/ https://www.ncbi.nlm.nih.gov/pubmed/32455728 http://dx.doi.org/10.3390/cells9051276 |
Ejemplares similares
-
Silibinin efficacy in a rat model of pulmonary arterial hypertension using monocrotaline and chronic hypoxia
por: Zhang, Tingting, et al.
Publicado: (2019) -
High expression of CXCR4 and stem cell markers in a monocrotaline and chronic hypoxia-induced rat model of pulmonary arterial hypertension
por: Zhang, Tingting, et al.
Publicado: (2018) -
Prospective In Vitro Models of Channelopathies and Cardiomyopathies
por: Kawaguchi, Nanako, et al.
Publicado: (2012) -
Therapeutic Efficacy of Valproic Acid in a Combined Monocrotaline and Chronic Hypoxia Rat Model of Severe Pulmonary Hypertension
por: Lan, Beidi, et al.
Publicado: (2015) -
Induced Pluripotent Stem Cell-Derived Cardiomyocytes with SCN5A R1623Q Mutation Associated with Severe Long QT Syndrome in Fetuses and Neonates Recapitulates Pathophysiological Phenotypes
por: Hayama, Emiko, et al.
Publicado: (2021)